{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:28:25Z","timestamp":1780410505767,"version":"3.54.1"},"reference-count":35,"publisher":"BMJ","issue":"12","funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,11,7]]},"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) cohort was established in Italy in 2016 to evaluate the overall efficacy and tolerability of dolutegravir (DTG)-based antiretroviral (ARV) regimens in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The ODOACRE cohort enrols all adult HIV-1-infected patients, both treatment-na\u00efve and treatment-experienced, starting a DTG-based ARV regimen, in 11 clinical centres in Italy from 2014.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings to date<\/jats:title>\n                    <jats:p>In recent years, various works by the ODOACRE cohort have been produced, demonstrating the high efficacy and tolerability of DTG-based ARV regimens in clinical practice, both in ART-na\u00efve (in the setting of acute HIV-1 infection and late presenters patient) and experienced patients. We confirmed the virological efficacy of DTG-based regimens and we evaluated predictors of virological failure. We investigated cause of discontinuation and evaluated tolerability and metabolic profile of the regimens. Within these investigations, we explored particularly the use of DTG in simplification in two-drug regimen with either rilpivirine or lamivudine. We also compared DTG-based regimens with other integrase inhibitors in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Future plans<\/jats:title>\n                    <jats:p>To continue to study long-term efficacy and tolerability of DTG-based regimens is the purpose of the ODOACRE cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-029960","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T05:40:47Z","timestamp":1575351647000},"page":"e029960","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)"],"prefix":"10.1136","volume":"9","author":[{"given":"Arturo","family":"Ciccullo","sequence":"first","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Facolt\u00e0 di Medicina e Chirurgia, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-9976","authenticated-orcid":false,"given":"Gianmaria","family":"Baldin","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Facolt\u00e0 di Medicina e Chirurgia, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"Capetti","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano Dipartimento di Scienze Cliniche Luigi Sacco, Milano, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Modena e Reggio Emilia Facolt\u00e0 di Medicina e Chirurgia, Modena, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetana","family":"Sterrantino","sequence":"additional","affiliation":[{"name":"Division of Tropical and Infectious Diseases, Azienda Ospedaliera Careggi, Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Latini","sequence":"additional","affiliation":[{"name":"Infectious Dermatology and Allergology Unit, IFO, Roma, Lazio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[{"name":"Department of Clinical, Surgical and Experimental Sciences, Sassari University Hospital, Sassari, Sardegna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Celani","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Universita degli Studi di Roma La Sapienza, Roma, Lazio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vignale","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinic\u2013 Department of Medicine and Science of Aging, School of Medicine, \u201cG. d\u2019Annunzio\" University, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rossetti","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Siena Facolt\u00e0 di Medicina e Chirurgia, Siena, Toscana, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Dusina","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Facolt\u00e0 di Medicina e Chirurgia, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Cossu","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano Dipartimento di Scienze Cliniche Luigi Sacco, Milano, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibilla","family":"Restelli","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano Dipartimento di Scienze Cliniche Luigi Sacco, Milano, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gennari","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Modena e Reggio Emilia Facolt\u00e0 di Medicina e Chirurgia, Modena, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lagi","sequence":"additional","affiliation":[{"name":"Division of Tropical and Infectious Diseases, Azienda Ospedaliera Careggi, Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-4289","authenticated-orcid":false,"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano Dipartimento di Scienze Cliniche Luigi Sacco, Milano, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Colafigli","sequence":"additional","affiliation":[{"name":"Infectious Dermatology and Allergology Unit, IFO, Roma, Lazio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Brescini","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Politecnica delle Marche Facolt\u00e0 di Medicina e Chirurgia, Ancona, Marche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Borghetti","sequence":"additional","affiliation":[{"name":"UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Modena e Reggio Emilia Facolt\u00e0 di Medicina e Chirurgia, Modena, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-9990","authenticated-orcid":false,"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano Dipartimento di Scienze Cliniche Luigi Sacco, Milano, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Facolt\u00e0 di Medicina e Chirurgia, Roma, Italy"},{"name":"UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"2025121411424676000_9.12.e029960.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"2025121411424676000_9.12.e029960.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2626-z","article-title":"Cardiovascular risk and dyslipidemia among persons living with HIV: a review","volume":"17","author":"Maggi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2025121411424676000_9.12.e029960.3","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32801022eb"},{"key":"2025121411424676000_9.12.e029960.4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.JAA.0000475465.07971.19","article-title":"Hiv pharmacotherapy: a review of integrase inhibitors","volume":"29","author":"Wong","year":"2016","journal-title":"JAAPA"},{"key":"2025121411424676000_9.12.e029960.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"2025121411424676000_9.12.e029960.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70257-3"},{"key":"2025121411424676000_9.12.e029960.7","unstructured":"Pappa K , Baumgarten A , Felizarta F , et al . Once daily dolutegravir + abacavir\/lamivudine is superior to efavirenz\/tenofovir\/emtricitabine in treatment-na\u00efve HIV subjects: 144-Week Results\u2014SINGLE (ING114467). Washington, DC: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2014."},{"key":"2025121411424676000_9.12.e029960.8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis750"},{"key":"2025121411424676000_9.12.e029960.9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu051"},{"key":"2025121411424676000_9.12.e029960.10","unstructured":"Vavro G , Huang J , Avatapally C , et al . Durable efficacy and limited integrase resistance in subjects receiving dolutegravir after failing a prior INI regimen: week 48 results from VIKING-3 (Abstract O_10). Barcelona, Spain: 12th European Workshop on HIV & Hepatitis, 2014."},{"key":"2025121411424676000_9.12.e029960.11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/14656566.2018.1457648","article-title":"Current and emerging two-drug approaches for HIV-1 therapy in ART-na\u00efve and ART-experienced, virologically suppressed patients","volume":"19","author":"Rossetti","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2025121411424676000_9.12.e029960.12","unstructured":"DHHS . Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services, 2017."},{"key":"2025121411424676000_9.12.e029960.13","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12468"},{"key":"2025121411424676000_9.12.e029960.14","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1097\/QAD.0000000000001279","article-title":"Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice","volume":"30","author":"de Boer","year":"2016","journal-title":"AIDS"},{"key":"2025121411424676000_9.12.e029960.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807653"},{"key":"2025121411424676000_9.12.e029960.16","doi-asserted-by":"crossref","unstructured":"Bourgi K , Rebeiro PF , Turner M , et al . Greater weight gain in treatment na\u00efve persons starting Dolutegravir-Based antiretroviral therapy. Clin Infect Dis 2019:ciz407.doi:10.1093\/cid\/ciz407","DOI":"10.1093\/cid\/ciz407"},{"key":"2025121411424676000_9.12.e029960.17","doi-asserted-by":"publisher","DOI":"10.1310\/hct1503-87"},{"key":"2025121411424676000_9.12.e029960.18","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048918"},{"key":"2025121411424676000_9.12.e029960.19","unstructured":"Linee Guida Italiane sull\u2019utilizzo della Terapia Antiretrovirale e la gestione diagnostico-clinica delle persone con infezione da HIV-1 \u2013 Edizione 2017."},{"key":"2025121411424676000_9.12.e029960.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"2025121411424676000_9.12.e029960.21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/1060028018758432","article-title":"Dolutegravir dual therapy as maintenance treatment in HIV-infected patients: a review","volume":"52","author":"Boswell","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2025121411424676000_9.12.e029960.22","doi-asserted-by":"crossref","unstructured":"Joly V , Burdet C , Landman R , et al . Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother 2018.","DOI":"10.1093\/jac\/dky467"},{"key":"2025121411424676000_9.12.e029960.23","unstructured":"Cahn P , Madero JS , Arribas JR , et al . Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2018."},{"key":"2025121411424676000_9.12.e029960.24","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268819000098","article-title":"Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016","volume":"147","author":"Bellino","year":"2019","journal-title":"Epidemiol Infect"},{"key":"2025121411424676000_9.12.e029960.25","unstructured":"Borgheti A , Ciccullo A , Lombardi F , et al . Gss of NRTI-BACKBONE predicts time to virological failure of INI-BASED regimens. Abstract 547, 26\u00b0 conference on retroviruses and opportunistic infections (CROI), Seattle, USA 2019."},{"key":"2025121411424676000_9.12.e029960.26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/QAD.0000000000001357","article-title":"Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients","volume":"31","author":"Borghetti","year":"2017","journal-title":"AIDS"},{"key":"2025121411424676000_9.12.e029960.27","doi-asserted-by":"crossref","unstructured":"Baldin G , Ciccullo A , Capetti A , et al . Efficacy and safety of switching to dolutegravir plus emtricitabine\/tenofovir disoproxil fumarate (TDF) or elvitegravir\/cobicistat\/emtricitabine\/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study. HIV Med 2018.","DOI":"10.1111\/hiv.12688"},{"key":"2025121411424676000_9.12.e029960.28","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/1060028018761600","article-title":"Dolutegravir plus rilpivirine as a switch option in cART-Experienced patients: 96-Week data","volume":"52","author":"Capetti","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2025121411424676000_9.12.e029960.29","doi-asserted-by":"crossref","unstructured":"Borghetti A , Baldin G , Lombardi F , et al . Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med 2018.","DOI":"10.1111\/hiv.12611"},{"key":"2025121411424676000_9.12.e029960.30","doi-asserted-by":"crossref","unstructured":"Ciccullo A , Baldin G , Capetti A , et al . A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. Antivir Ther 2018.","DOI":"10.3851\/IMP3270"},{"key":"2025121411424676000_9.12.e029960.31","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2755-4","article-title":"A dual regimen of ritonavir\/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks\u2019 observational data","volume":"17","author":"Capetti","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2025121411424676000_9.12.e029960.32","article-title":"Efficacy and safety of Dolutegravir-Based regimens in advanced HIV-infected na\u00efve patients: results from a multicenter cohort study. Abstract supplement HIV Glasgow 2018","volume":"21","author":"Rossetti","year":"2018","journal-title":"Journal of the International AIDS Society"},{"key":"2025121411424676000_9.12.e029960.33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijantimicag.2019.06.003","article-title":"Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: a multicenter retrospective cohort study","volume":"54","author":"Lagi","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2025121411424676000_9.12.e029960.34","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/QAD.0000000000001495","article-title":"Dolutegravir and weight gain: an unexpected bothering side effect?","volume":"31","author":"Menard","year":"2017","journal-title":"AIDS"},{"key":"2025121411424676000_9.12.e029960.35","unstructured":"ClinicalTrial.gov . Switch study to evaluate dolutegravir plus lamivudine in virologically suppressed human immunodeficiency virus type 1 positive adults (tango). ClinicalTrials.gov identifier NCT03446573 . Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03446573"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-029960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:42:55Z","timestamp":1765741375000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-029960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,2]]},"published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1136\/bmjopen-2019-029960"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-029960","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}